Literature DB >> 23824810

Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep.

Cristina C P Celma1, Mark Boyce, Piet A van Rijn, Michael Eschbaumer, Kerstin Wernike, Bernd Hoffmann, Martin Beer, Andy Haegeman, Kris De Clercq, Polly Roy.   

Abstract

Since 1998, 9 of the 26 serotypes of bluetongue virus (BTV) have spread throughout Europe, and serotype 8 has suddenly emerged in northern Europe, causing considerable economic losses, direct (mortality and morbidity) but also indirect, due to restriction in animal movements. Therefore, many new types of vaccines, particularly subunit vaccines, with improved safety and efficacy for a broad range of BTV serotypes are currently being developed by different laboratories. Here we exploited a reverse genetics-based replication-deficient BTV serotype 1 (BTV-1) (disabled infectious single cycle [DISC]) strain to generate a series of DISC vaccine strains. Cattle and sheep were vaccinated with these viruses either singly or in cocktail form as a multivalent vaccine candidate. All vaccinated animals were seroconverted and developed neutralizing antibody responses to their respective serotypes. After challenge with the virulent strains at 21 days postvaccination, vaccinated animals showed neither any clinical reaction nor viremia. Further, there was no interference with protection with a multivalent preparation of six distinct DISC viruses. These data indicate that a very-rapid-response vaccine could be developed based on which serotypes are circulating in the population at the time of an outbreak.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23824810      PMCID: PMC3754119          DOI: 10.1128/JVI.01514-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  Virus-like particles as immunogens.

Authors:  Rob Noad; Polly Roy
Journal:  Trends Microbiol       Date:  2003-09       Impact factor: 17.079

2.  Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.

Authors:  Josh D Boone; Udeni B Balasuriya; Kemal Karaca; Jean-Christophe Audonnet; Jiansheng Yao; Ling He; Robert Nordgren; Federica Monaco; Giovanni Savini; Ian A Gardner; N James Maclachlan
Journal:  Vaccine       Date:  2006-09-05       Impact factor: 3.641

3.  Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.

Authors:  P Roy; D H Bishop; H LeBlois; B J Erasmus
Journal:  Vaccine       Date:  1994-07       Impact factor: 3.641

4.  Sequence analysis of bluetongue virus serotype 8 from the Netherlands 2006 and comparison to other European strains.

Authors:  Sushila Maan; Narender S Maan; Natalie Ross-smith; Carrie A Batten; Andrew E Shaw; Simon J Anthony; Alan R Samuel; Karin E Darpel; Eva Veronesi; Chris A L Oura; Karam P Singh; Kyriaki Nomikou; Abraham C Potgieter; Houssam Attoui; Eugene van Rooij; Piet van Rijn; Kris De Clercq; Frank Vandenbussche; Stéphan Zientara; Emmanuel Bréard; Corinne Sailleau; Martin Beer; Bernd Hoffman; Philip S Mellor; Peter P C Mertens
Journal:  Virology       Date:  2008-08-01       Impact factor: 3.616

5.  Evaluation of antibody-ELISA and real-time RT-PCR for the diagnosis and profiling of bluetongue virus serotype 8 during the epidemic in Belgium in 2006.

Authors:  Frank Vandenbussche; Tine Vanbinst; Bart Verheyden; Wesley Van Dessel; Lien Demeestere; Philippe Houdart; Guido Bertels; Nicolas Praet; Dirk Berkvens; Koen Mintiens; Nesya Goris; Kris De Clercq
Journal:  Vet Microbiol       Date:  2007-11-07       Impact factor: 3.293

6.  Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants.

Authors:  Aurélie Perrin; Emmanuel Albina; Emmanuel Bréard; Corinne Sailleau; Sylvie Promé; Colette Grillet; Olivier Kwiatek; Pierre Russo; Richard Thiéry; Stephan Zientara; Catherine Cêtre-Sossah
Journal:  Vaccine       Date:  2007-07-16       Impact factor: 3.641

7.  Use of real-time RT-PCR as a rapid molecular approach for differentiation of field and vaccine strains of bluetongue virus serotypes 2 and 9.

Authors:  Gabriella Elia; Giovanni Savini; Nicola Decaro; Vito Martella; Liana Teodori; Claudia Casaccia; Luigina Di Gialleonardo; Eleonora Lorusso; Vincenzo Caporale; Canio Buonavoglia
Journal:  Mol Cell Probes       Date:  2007-07-03       Impact factor: 2.365

Review 8.  Climate change and the recent emergence of bluetongue in Europe.

Authors:  Bethan V Purse; Philip S Mellor; David J Rogers; Alan R Samuel; Peter P C Mertens; Matthew Baylis
Journal:  Nat Rev Microbiol       Date:  2005-02       Impact factor: 60.633

9.  Rapid cDNA synthesis and sequencing techniques for the genetic study of bluetongue and other dsRNA viruses.

Authors:  Sushila Maan; Shujing Rao; Narender Singh Maan; Simon John Anthony; Houssam Attoui; Alan Richard Samuel; Peter Paul Clement Mertens
Journal:  J Virol Methods       Date:  2007-04-11       Impact factor: 2.014

10.  Minimum requirements for bluetongue virus primary replication in vivo.

Authors:  Eiko Matsuo; Polly Roy
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

View more
  20 in total

1.  Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals.

Authors:  Jenna Anderson; Emmanuel Bréard; Karin Lövgren Bengtsson; Kjell-Olov Grönvik; Stéphan Zientara; Jean-Francois Valarcher; Sara Hägglund
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

2.  The 13th International Double-Stranded RNA Virus Symposium, Houffalize, Belgium, 24 to 28 September 2018.

Authors:  Ulrich Desselberger
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

3.  An updated review on bluetongue virus: epidemiology, pathobiology, and advances in diagnosis and control with special reference to India.

Authors:  Mani Saminathan; Karam Pal Singh; Jaynudin Hajibhai Khorajiya; Murali Dinesh; Sobharani Vineetha; Madhulina Maity; At Faslu Rahman; Jyoti Misri; Yashpal Singh Malik; Vivek Kumar Gupta; Raj Kumar Singh; Kuldeep Dhama
Journal:  Vet Q       Date:  2020-12       Impact factor: 3.320

Review 4.  The molecular biology of Bluetongue virus replication.

Authors:  Avnish Patel; Polly Roy
Journal:  Virus Res       Date:  2013-12-25       Impact factor: 3.303

5.  Entry-competent-replication-abortive African horse sickness virus strains elicit robust immunity in ponies against all serotypes.

Authors:  Edward Sullivan; Sylvie Lecollinet; Adeline Kerviel; Erika Hue; Stéphane Pronost; Cécile Beck; Marine Dumarest; Stephan Zientara; Polly Roy
Journal:  Vaccine       Date:  2021-05-03       Impact factor: 3.641

6.  VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.

Authors:  Sandra G P van de Water; René G P van Gennip; Christiaan A Potgieter; Isabel M Wright; Piet A van Rijn
Journal:  J Virol       Date:  2015-06-10       Impact factor: 5.103

7.  Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.

Authors:  Stefanie Kochinger; Nathalie Renevey; Martin A Hofmann; Gert Zimmer
Journal:  Vet Res       Date:  2014-06-13       Impact factor: 3.683

8.  A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus.

Authors:  Sandro Filipe Nunes; Claude Hamers; Maxime Ratinier; Andrew Shaw; Sylvie Brunet; Pascal Hudelet; Massimo Palmarini
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

9.  The Bluetongue Disabled Infectious Single Animal (DISA) Vaccine Platform Based on Deletion NS3/NS3a Protein Is Safe and Protective in Cattle and Enables DIVA.

Authors:  Piet A van Rijn; Mieke A Maris-Veldhuis; René G P van Gennip
Journal:  Viruses       Date:  2021-05-07       Impact factor: 5.048

10.  Requirements and comparative analysis of reverse genetics for bluetongue virus (BTV) and African horse sickness virus (AHSV).

Authors:  Piet A van Rijn; Sandra G P van de Water; Femke Feenstra; René G P van Gennip
Journal:  Virol J       Date:  2016-07-02       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.